Green Cross Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Green Cross with three other
companies in this sector in South Korea:
sales of 949.08 billion Korean Won [US$839.94 million]
of which 87%
was Bio Business Division),
Samsung Biologics Co Ltd
(464.63 billion Korean Won [US$411.20 million]
of which 100%
was Biological Medicine Production), and
Celltrion HealthCare Co Ltd
(920.92 billion Korean Won [US$815.02 million]
Green Cross reported sales of 1.29 trillion Korean Won (US$1.14 billion)
December of 2017.
increase of 7.5%
versus 2016, when the company's sales were 1.20 trillion Korean Won.
Sales at Green Cross have increased during each of the previous five years
(and since 2012, sales have increased a total of 59%).
Sales of Greencross Genome saw an increase
that was more than double the company's growth rate: sales were up
43.9% in 2017, from
5.14 billion Korean Won to 7.40 billion Korean Won.
Green Cross also saw significant increases in sales in
Greencross Ms (up 13.9% to 98.11 billion Korean Won)
Gcjbp (up 23.0% to 45.07 billion Korean Won)
Not all segments of Green Cross experienced an increase in sales in 2017:
sales of Invacfarm fell 9.6% to 14.75 billion Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).